文献速递泌尿男性生殖肿瘤

低剂量阿比特龙随餐对比标准剂量治疗去势抵抗性前列腺癌的随机II期研究

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2018-03-28

这项国际随机II期研究纳入72例进展性去势抵抗性前列腺癌患者,比较低剂量阿比特龙(250mg随低脂餐)与标准剂量(1000mg空腹)的疗效。主要终点PSA对数变化显示低剂量组非劣效于标准剂量组,12周PSA反应率分别为58%和50%,中位PFS均约9个月。

要点

  • 低剂量阿比特龙随低脂餐在PSA指标上非劣效于标准剂量空腹给药
  • 两组PSA反应率与中位PFS均无显著差异,雄激素下降程度相似
  • 标准剂量组阿比特龙血药浓度更高,但未转化为疗效优势

核心结论

  • 低剂量阿比特龙(250mg随低脂早餐)在PSA指标上非劣效于标准剂量(1000mg空腹)。
  • 考虑到药物经济学影响,该数据值得处方者、支付方和患者考虑。

研究设计与样本

  • 前瞻性国际随机II期研究,纳入72例进展性去势抵抗性前列腺癌患者,来自美国和新加坡7家机构。
  • 患者随机分配至标准剂量组或低剂量组,两组均接受泼尼松5mg每日两次。
  • 主要终点为PSA对数变化,采用非劣效性设计;次要终点包括PFS、PSA反应、雄激素水平变化和药代动力学。

主要发现

  • 12周时低剂量组PSA平均对数变化为-1.59,标准剂量组为-1.19,低剂量非劣效性成立。
  • PSA反应率(≥50%下降)低剂量组为58%,标准剂量组为50%。
  • 两组中位PFS均约9个月,雄激素水平下降程度相似。
  • 标准剂量组阿比特龙血药浓度更高,但PSA反应和PFS无差异。

关键数值与推荐

  • 低剂量组:阿比特龙250mg随低脂餐;标准剂量组:阿比特龙1000mg空腹。
  • PSA反应定义为较基线下降≥50%。
  • 主要终点非劣效性依据预设标准判定。

临床怎么用

  • 低剂量阿比特龙随低脂餐可作为标准剂量空腹给药的替代方案,尤其考虑药物经济学因素时。
  • 需进一步研究评估该方法的长期疗效。

局限性

  • 样本量较小(n=72),为II期研究。
  • 随访时间有限,长期疗效有待确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Abiraterone acetate (AA) is a standard of care for metastatic castration-resistant prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting conditions in its pivotal trials. We sought to test the hypothesis that low-dose AA (LOW; 250 mg with a low-fat meal) would have comparable activity to standard AA (STD; 1,000 mg fasting) in patients with CRPC. Patients and Methods Patients (n = 72) with progressive CRPC from seven institutions in the United States and Singapore were randomly assigned to STD or LOW. Both arms received prednisone 5 mg twice daily. Prostate-specific antigen (PSA) was assessed monthly, and testosterone/dehydroepiandrosterone sulfate were assessed every 12 weeks with disease burden radiographic assessments. Plasma was collected for drug concentrations. Log change in PSA, as a pharmacodynamic biomarker for efficacy, was the primary end point, using a noninferiority design. Progression-free survival (PFS), PSA response (≥ 50% reduction), change in androgen levels, and pharmacokinetics were secondary end points. Results Thirty-six patients were accrued to both arms. At 12 weeks, there was a greater effect on PSA in the LOW arm (mean log change, -1.59) compared with STD (-1.19), and noninferiority of LOW was established according to predefined criteria. The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups. Androgen levels decreased similarly in both arms. Although there was no difference in PSA response or PFS, abiraterone concentrations were higher in STD. Conclusion Low-dose AA (with low-fat breakfast) is noninferior to standard dosing with respect to PSA metrics. Given the pharmacoeconomic implications, these data warrant consideration by prescribers, payers, and patients. Additional studies are indicated to assess the long-term efficacy of this approach.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018. PMID: 29590007. doi:10.1200/JCO.2017.76.4381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。